<DOC>
	<DOCNO>NCT02360059</DOCNO>
	<brief_summary>The goal clinical research study learn metformin help control nerve damage ( loss motor sensory function ) may cause treatment paclitaxel patient breast cancer . In study , metformin compare placebo . A placebo drug . It look like study drug , design treat disease illness . It design compare study drug learn study drug real effect .</brief_summary>
	<brief_title>Metformin Reduction Paclitaxel-Related Neuropathy Patients With Breast Cancer</brief_title>
	<detailed_description>Study Groups : If find eligible take part study , randomly assign ( roll dice ) 1 2 group . This do one know one study group well , , bad group . You 1 3 chance Group 1 2 3 chance Group 2 . - If Group 1 , take placebo pill . - If Group 2 , take metformin pill . Neither study staff know receive study drug placebo . However , need safety , study staff able find receiving . Study Drug Administration : You take pill 2 time day time every day , preferably food ( example , breakfast dinner ) . You start take pill 12 day paclitaxel treatment start . This call `` adaptation period . '' It mean allow body get use study pill . The study staff check allergic reaction negative reaction pill period . If tolerate pill , take study . About every 3 week receive paclitaxel , bring study drug/placebo container ( along leftover pill ) clinic . The study staff count number pill take . Study Visits : Every week study , either clinic visit phone , study staff ask side effect may , take study drug/placebo , many pill take far . The call take 10-15 minute . About 2 week start paclitaxel : - You complete questionnaire numbness symptom . It take 15 minute complete questionnaire . - You complete 3 sensory fine-motor test . These test show researcher sensitive touching thing small bump well able pick small object . It take 15 minute complete test . - If possible , blood ( 8 teaspoon ) also draw test marker inflammation . Markers inflammation biomarkers find blood may relate symptom . These blood sample study collect drawn routine blood draw already . At 1-2 day start paclitaxel : - You complete questionnaire numbness symptom . - You complete sensory fine-motor test . - Blood ( 8 teaspoon ) draw test marker inflammation , routine blood sample also draw day . Every week receive paclitaxel , complete questionnaire clinic phone symptom may , symptom may affect daily activity . This questionnaire take 5 minute complete . About every 3 week receive paclitaxel , clinic visit : - You complete questionnaire numbness . - You also complete sensory fine-motor dexterity test . At Weeks 6 12 receiving paclitaxel , clinic visit , blood ( 8 teaspoon ) draw test marker inflammation , routine blood sample also draw day . At Week 12 receive paclitaxel , clinic visit , complete questionnaire satisfy study drug/placebo . Completing questionnaire take 5 minute . Length Study : You may take study drug/placebo 12 week . You longer able take study drug/placebo disease get bad , intolerable side effect occur , unable follow study direction . Your participation study end-of-study visit . End-of-Study Visit : About 4 week finish receive study drug/placebo : - You complete questionnaire numbness symptom . - You complete sensory fine-motor test . - Blood ( 8 teaspoon ) draw test marker inflammation , routine blood sample also draw day . This investigational study . Metformin FDA approve commercially available treatment type diabetes . Its use study investigational . The study doctor explain study drug design work . Up 42 participant enrol study . All take part Harris Health System .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Patients histologically confirm invasive breast cancer , stage I IV , treat Lyndon B. Johnson General Hospital Harris Health System . 2 . Patients = &gt; 18 year old &lt; 75 year old . 3 . Patients schedule undergo paclitaxel chemotherapy breast cancer . 4 . Patients adequate renal function , evidence laboratory value = &lt; 3 month old : epidermal growth factor receptor ( eGFR ) = &gt; 60 mL/min/1.73m2 . 5 . Patients adequate hepatic function per institutional testing standard , evidence laboratory value = &lt; 3 month old : ( 1 ) The screening result total bilirubin must &lt; 1.5 time upper limit normal . ( 2 ) The screening result aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) must &lt; 2 time upper limit normal . 6 . Patients speak English and/or Spanish . 7 . Patients willing able review , understand , provide write consent . 8 . Patients Eastern Cooperative Oncology performance status 0 1 . 1 . Patients history know diagnosis diabetes accord national guideline ( fast plasma glucose &gt; = 126 mg/dL random plasma glucose &gt; = 200 mg/dL ) , evidence laboratory value &lt; = 3 month old ) . 2 . Patients use carbonic anhydrase inhibitor ( acetazolamide [ Diamox速 ] , brinzolamide [ Azopt速 ] , methazolamide [ Neptazane速 ] , dorzolamide [ Trusopt速 ] , pomegranate ellagitannins ) , cimetidine , topiramate . 3 . Patients enrol another symptom management trial . 4 . Patients nerve pathology clinically identify neuropathy . 5 . Patients history clinically significant cutaneous drug reaction , hypersensitivity reaction , anaphylaxis , serious adverse reaction medication use study . 6 . Patients condition associate increase risk metforminassociated lactic acidosis ( e.g. , congestive heart failure define New York Heart Association Class III IV functional status , history acidosis type ) . 7 . Patients intestinal issue , include malabsorption syndrome , disease significantly affect gastrointestinal function , resection stomach small bowel . 8 . Patients pregnant exclude . Premenopausal woman must negative pregnancy test . Patients post menopausal , hysterectomy need pregnancy test . 9 . Patients condition precludes use study medication determine treat physician . 10 . Patients diagnosis hepatitis HIV . 11 . Patients currently receive schedule receive chemotherapy infusion Adriamycin/Cyclophosphamide prior initiation metformin adaptation phase eligible . Patients receive Adriamycin/Cyclophosphamide must schedule least 8 day postchemotherapy infusion prior initiation metformin adaptation phase order eligible . 12 . Patients currently use metformin ( eg , Fortamet , Glucophage , Glucophage XR , Glumetza , Riomet ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Neuropathy</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Metformin</keyword>
	<keyword>Metformin ER</keyword>
	<keyword>Placebo</keyword>
	<keyword>Sugar pill</keyword>
	<keyword>Questionnaires</keyword>
	<keyword>Sensory test</keyword>
	<keyword>Fine-motor test</keyword>
	<keyword>Surveys</keyword>
</DOC>